0ILL.L • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold 0ILL.L in your mock portfolio yet.
With EPS of €3.32 and a PE ratio of 19.53, Rovi is priced at a moderate premium that suggests the market expects steady, not explosive, earnings growth. The valuation is neither clearly cheap nor excessively expensive for a profitable specialty pharma company. Without detailed revenue and margin history, the data points to a solid but not obviously mispriced earnings profile.
The stock is trading at €64.90, about 20% above its 200‑day moving average of €53.85, and is up 8.4% over the last month, indicating a medium‑term uptrend. However, the RSI at 46.64 is neutral, suggesting neither overbought nor oversold conditions. Overall, price action shows constructive momentum but not strong enough to be clearly bullish from a technical standpoint.
Alternative data for Rovi is broadly stable with mild positive signals in hiring and a solid professional network presence. Website traffic and app downloads are flat month over month, suggesting no near‑term demand spike. Hiring growth and a large LinkedIn following point to ongoing operational activity and brand strength, but social media momentum is modest.
Taken together, Rovi’s valuation, technical profile, and alternative data suggest a neutral outlook with a slight constructive tilt. The company appears solidly profitable and in a medium‑term uptrend, but without strong evidence of accelerating fundamentals or demand that would justify a clearly bullish stance. The stock seems reasonably priced for steady performance rather than a major re‑rating.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: